Clinical Observation of Oxaliplatin Combined with Tegafur in the Treatment of Advanced Primary Hepatic Carcinoma after Transcatheter Arterial Chemoembolization / 中国药房

ABSTRACT

OBJECTIVE:To observe therapeutic efficacy and safety of oxaliplatin combined with tegafur in the treatment of ad-vanced primary hepatic carcinoma after transcatheter arterial chemoembolization(TACE). METHODS:120 patients with advanced primary hepatic carcinoma were selected from our hospital during Apr. 2011-Apr. 2013,and then divided into control group and ob-servation group according to random number table,with 60 cases in each group. Both groups received TACE. Control group was given Oxaliplatin injection 0.08 g/m2 after surgery via catheter arterial puming,within 4 h;observation group was additionally giv-en Tegafur capsules 40 mg/m2,po,bid,on the basis of control group. Both group received treatment for 4 months. Clinical efficacy, hepatic function indexes [ALT,AST,TBIL,DBIL] and alpha-fetoprotein(AFP)level were observed in 2 groups;the occurrence of ADR during treatment was recorded as well as 1-year,2-year,3-year follow-up survival rates. RESULTS:Before treatment, there was no statistical significance in hepatic function indexes and AFP(P>0.05). After treatment,disease control rate(78.33%) and clinical benefit rate(93.33%)of observation group were significantly higher than those of control group(48.335,71.67%), with statistical significance (P0.05). 1-year,2-year,3-year fol-low-up survival rates of observation group were significant higher than control group,with statistical significance(P<0.05). CON-CLUSIONSOxaliplatin combined with tegafur is effective for advanced primary hepatic carcinoma after TACE with good safety.